Clinical Trial Update: Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pembrolizumab plus chemotherapy as first-line treatment for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Pancreatic Cancer, Chemotherapy Effect | Phase 2 | Status: ACTIVE_NOT_RECRUITING